THIOGENESIS THERAPEUTICS, CORP.

ANNOUNCES TSXV FINAL APPROVAL OF QT AND RESUMPTION OF TRADING; GRANT OF STOCK OPTIONS

Toronto, Ontario — (April 12, 2022) – Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("TTI" or the "Company") (formerly Rozdil Capital Corporation) is pleased to announce that the TSX Venture Exchange (the "Exchange") has granted final approval to the completion of its Qualifying Transaction. A final Exchange Bulletin was issued on April 11, 2022. Resumption in trading in the common shares of TTI is scheduled to commence on April 13, 2022 under the trading symbol "TTI" and CUSIP/ISIN 88410L102.

Grant of Stock Options

The Company announces that it has approved the grant of 50,000 stock options pursuant to the Company's Stock Option Plan to a consultant retained by the Company. The options are exercisable at $0.35 per share and, if not exercised, expire March 31, 2025, subject to earlier expiration in accordance with the Stock Option Plan and the applicable policies of the TSX Venture Exchange.

Correction related to Escrowed Securities

The Company's April 5, 2022 news release incorrectly disclosed the total number of shares held in the Exchange CPC Escrow Agreement. The correct number of shares subject to the Exchange CPC Escrow Agreement is 2,725,000.

Forward-Looking Statements Disclaimer

Certain statements contained in this press release constitute "forward-looking information" as such term is defined in applicable Canadian securities legislation. The words "may", "would", "could", "should", "potential", "will", "seek", "intend", "plan", "anticipate", "believe", "estimate", "expect" and similar expressions as they relate to TTI are intended to identify forward-looking information. All statements other than statements of historical fact may be forward-looking information. Such statements reflect the Company's current views and intentions with respect to future events, and current information available to them, and are subject to certain risks, uncertainties and assumptions Many factors could cause the actual results, performance or achievements that may be expressed or implied by such forward-looking information to vary from those described herein should one or more of these risks or uncertainties materialize. Such factors include but are not limited to: changes in economic conditions or financial markets; increases in costs; litigation; legislative and other judicial, regulatory, political and competitive developments; and operational difficulties. This list is not exhaustive of the factors that may affect forward-looking information. These and other factors should be considered carefully, and readers should not place undue reliance on such forward-looking information. Should any factor affect the Company in an unexpected manner, or should assumptions underlying the forward-looking information prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking information is expressly qualified in its entirety by this cautionary statement. Moreover, the Company does not assume responsibility for the accuracy or completeness of such forward-looking information. The forward-looking information included in this press release is made as of the date of this press release and the Company undertakes no obligation to publicly update or revise any forward-looking information, other than as required by applicable law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

For further information, please contact:

Brook Riggins, Director and Secretary
Email: briggins@thiogenesis.com
Tel.: +420 776 659 259